Premium
Genetic vaccination strategies for enhanced cellular, humoral and mucosal immunity
Author(s) -
Ramsay Alistair J.,
Kent Stephen J.,
Strugnell Richard A.,
Suhrbier Andreas,
Thomson Scott A.,
Ramshaw Ian A.,
Raima Alisiarr J.,
Kent Stephen J.,
Strugnell Richard A.,
Suhrbicr Andreas,
Thomson Scott A,
Ramshaw Ian A.
Publication year - 1999
Publication title -
immunological reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.839
H-Index - 223
eISSN - 1600-065X
pISSN - 0105-2896
DOI - 10.1111/j.1600-065x.1999.tb01341.x
Subject(s) - immune system , biology , immunology , dna vaccination , vaccination , immunity , humoral immunity , cd8 , antigen , cytotoxic t cell , cellular immunity , virology , immunization , genetics , in vitro
Summary: In this article, we describe several novel genetic vaccination strategies designed to facilitate the development of different types of immune responses. These include: the consecutive use of DNA and fowlpoxvirus vectors in “prime‐boost” strategies which induce greatly enhanced and sustained levels of both cell‐mediated immunity and humoral immunity, including mucosal responses; ii) the co‐expression of genes encoding cytokines and cell‐surface receptors, and the use of immunogenic carrier molecules, for immune modulation and/or Improved targeting of vector‐expressed vaccine antigens; acid iii) the expression of minimal immunogenic arnino acid sequences, particularly cytotoxic CD8+ T‐cell determinants, in “polytope” vector vaccines. The capacity to modulate and enhance specific immune responses by the use of approaches such as these may underpin the development of vaccines against diseases for which no effective strategies are currently available.